$111 Million is the total value of BML Capital Management, LLC's 31 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACET | Exit | ADICET BIO INC | $0 | – | -30,000 | -100.0% | -0.15% | – |
| Exit | CARISMA THERAPEUTICS INC | $0 | – | -411,398 | -100.0% | -1.10% | – | |
| JNCE | Exit | JOUNCE THERAPEUTICS INC | $0 | – | -1,087,961 | -100.0% | -1.74% | – |
| MTCR | Exit | METACRINE INC | $0 | – | -6,167,458 | -100.0% | -3.04% | – |
| Exit | EMBARK TECHNOLOGY INC | $0 | – | -1,285,390 | -100.0% | -3.12% | – | |
| Exit | DISC MEDICINE INC | $0 | – | -208,161 | -100.0% | -3.81% | – | |
| STSA | Exit | SATSUMA PHARMACEUTICALS INC | $0 | – | -6,440,000 | -100.0% | -3.89% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-07-24
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPDR SER TR | 4 | Q3 2023 | 16.9% |
| ADVERUM BIOTECHNOLOGIES INC | 4 | Q3 2023 | 7.4% |
| ELIEM THERAPEUTICS INC | 4 | Q3 2023 | 6.4% |
| ATHIRA PHARMA INC | 4 | Q3 2023 | 4.9% |
| ASTROTECH CORP | 4 | Q3 2023 | 2.8% |
| ARCA BIOPHARMA INC | 4 | Q3 2023 | 1.9% |
| FORTE BIOSCIENCES INC | 4 | Q3 2023 | 1.6% |
| VERRICA PHARMACEUTICALS INC | 4 | Q3 2023 | 2.9% |
| PASSAGE BIO INC | 4 | Q3 2023 | 1.7% |
| RETRACTABLE TECHNOLOGIES INC | 4 | Q3 2023 | 1.0% |
View BML Capital Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-04-24 |
| 13F-HR | 2024-04-23 |
| 13F-HR/A | 2024-02-02 |
| 13F-HR | 2024-01-30 |
| 13F-HR | 2023-10-23 |
| 13F-HR | 2023-07-24 |
| 13F-HR | 2023-04-14 |
| 13F-HR | 2023-02-13 |
View BML Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.